Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer.
about
Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer.Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis.Decreased gastrointestinal toxicity associated with a novel capecitabine schedule (7 days on and 7 days off): a systematic review.Dose selection for the investigational anticancer agent alisertib (MLN8237): Pharmacokinetics, pharmacodynamics, and exposure-safety relationships.Predictive Value of Early Skin Rash in Cetuximab-Based Therapy of Advanced Biliary Tract Cancer.
P2860
Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Fixed-dose capecitabine is fea ...... y in metastatic breast cancer.
@en
type
label
Fixed-dose capecitabine is fea ...... y in metastatic breast cancer.
@en
prefLabel
Fixed-dose capecitabine is fea ...... y in metastatic breast cancer.
@en
P2093
P2860
P1476
Fixed-dose capecitabine is fea ...... y in metastatic breast cancer.
@en
P2093
Antonio C Wolff
Deborah K Armstrong
Elizabeth Garrett-Mayer
Howard L McLeod
Janelle M Hoskins
John H Fetting
Laurie A Wright
Michelle A Rudek
Nancy E Davidson
P2860
P2888
P304
P356
10.1007/S10549-013-2516-Z
P407
P577
2013-04-16T00:00:00Z